Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases

Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases


Hauptsponsor: Methodist Health System

Quelle Methodist Health System
Kurze Zusammenfassung

This study will be a retrospective chart review of patients who have been diagnosed with the benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr. Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in Richardson, TX. The investigators plan to conduct an analysis of patients meeting the inclusion criteria from 2005 to present. Study will also be conducted by the PI, Sub-Is, surgery fellows, office staff and clinical research coordinator who are delegated to do by the PI. Data will be obtained by looking through either investigator's patients or through a national database. Data will be analyzed primarily by the study conductors.

detaillierte Beschreibung

It is reported in the literature that the treatment of any pancreatic disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. The investigator's goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality, and morbidity.

The main aim of this study is to evaluate and compare the outcomes from the investigator's decisions on multiple treatments of benign or malignant pancreatic diseases.There is a need to understand and improve the current diagnosis and treatment algorithm for pancreatic pathologies. Continued evaluation and study is imperative to ensure that national guidelines are improving to enhance patient cure and/or recovery.

All past patients who were treated for a particular benign or malignant pancreatic disease process under evaluation from 2005 to present will be included in this study.

Gesamtstatus Recruiting
Anfangsdatum March 5, 2019
Fertigstellungstermin January 30, 2025
Primäres Abschlussdatum January 30, 2025
Studientyp Observational
Primärer Ausgang
Messen Zeitfenster
Overall survival 2005 to 2019
Einschreibung 500

Probenahmeverfahren: Probability Sample


Inclusion Criteria:

- • All patients diagnosed and treated for pancreatic diseases, benign or malignant from 2005 to present

- Age ≥18 years

Exclusion Criteria:

- • Patients that are not diagnosed with or treated for pancreatic diseases

- Age < 18 years

Geschlecht: All

Mindestalter: 18 Years

Maximales Alter: N/A

Gesunde Freiwillige: No

Insgesamt offiziell
Nachname Rolle Zugehörigkeit
Dhiresh Jeyarajah, M.D. Principal Investigator Methodist Richardson Medical Center

Nachname: Crystee Cooper, DHEd

Telefon: 214-947-1280

Email: [email protected]

Einrichtung: Status: Kontakt: Trinity Surgical Consultants, Methodist Richardson Medical Center Dhiresh R Jeyarajah, MD 972-619-3500
Standort Länder

United States


April 2019

Verantwortliche Partei

Art: Sponsor

Hat den Zugriff erweitert No
Bedingung Durchsuchen
Patientendaten Undecided
Studiendesign Info

Beobachtungsmodell: Cohort

Zeitperspektive: Retrospective

Quelle: ClinicalTrials.gov